128 related articles for article (PubMed ID: 38368130)
1. Impact of HLA Eplet Mismatch on De Novo Donor Specific Antibody Formation After Kidney Transplantation.
Yanyiam P; Kantachuvesiri S; Thammanichanond D
Transplant Proc; 2024 Apr; 56(3):515-520. PubMed ID: 38368130
[TBL] [Abstract][Full Text] [Related]
2. Combined Analysis of HLA Class II Eplet Mismatch and Tacrolimus Levels for the Prediction of De Novo Donor Specific Antibody Development in Kidney Transplant Recipients.
Lee H; Min JW; Kang H; Lee H; Eum SH; Park Y; Yang CW; Chung BH; Oh EJ
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806362
[TBL] [Abstract][Full Text] [Related]
3. Eplet Mismatch Load and
Senev A; Coemans M; Lerut E; Van Sandt V; Kerkhofs J; Daniëls L; Driessche MV; Compernolle V; Sprangers B; Van Loon E; Callemeyn J; Claas F; Tambur AR; Verbeke G; Kuypers D; Emonds MP; Naesens M
J Am Soc Nephrol; 2020 Sep; 31(9):2193-2204. PubMed ID: 32764139
[TBL] [Abstract][Full Text] [Related]
4. HLA, Non-HLA Antibodies, and Eplet Mismatches in Pediatric Liver Transplantation: Observations From a Small, Single-Center Cohort.
Ekong UD; Antala S; Bow L; Sese D; Morotti R; Rodriguez-Davalos M; Gan G; Deng Y; Emre SH
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):6-17. PubMed ID: 30777518
[TBL] [Abstract][Full Text] [Related]
5. Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development.
Wiebe C; Rush DN; Nevins TE; Birk PE; Blydt-Hansen T; Gibson IW; Goldberg A; Ho J; Karpinski M; Pochinco D; Sharma A; Storsley L; Matas AJ; Nickerson PW
J Am Soc Nephrol; 2017 Nov; 28(11):3353-3362. PubMed ID: 28729289
[TBL] [Abstract][Full Text] [Related]
6. Association of HLA B- and T-cell molecular mismatches with HLA antibodies, rejection, and graft survival in pediatric kidney transplantation.
Gramkow AM; Baatrup JH; Gramkow ET; Thiesson HC; Koefoed-Nielsen P
Pediatr Transplant; 2024 Aug; 28(5):e14773. PubMed ID: 38808702
[TBL] [Abstract][Full Text] [Related]
7. Donor selection in pediatric kidney transplantation using DR and DQ eplet mismatching: A new histocompatibility paradigm.
Bryan CF; Chadha V; Warady BA
Pediatr Transplant; 2016 Nov; 20(7):926-930. PubMed ID: 27448994
[TBL] [Abstract][Full Text] [Related]
8. Eplet mismatches associated with de novo donor-specific HLA antibody in pediatric kidney transplant recipients.
Charnaya O; Jones J; Philogene MC; Chiang PY; Segev DL; Massie AB; Garonzik-Wang J
Pediatr Nephrol; 2021 Dec; 36(12):3971-3979. PubMed ID: 34100108
[TBL] [Abstract][Full Text] [Related]
9. HLA-DQ eplet mismatch load may identify kidney transplant patients eligible for tacrolimus withdrawal without donor-specific antibody formation after mesenchymal stromal cell therapy.
Bezstarosti S; Meziyerh S; Reinders MEJ; Voogt-Bakker K; Groeneweg KE; Roelen DL; Kers J; de Fijter JW; Heidt S
HLA; 2023 Jul; 102(1):3-12. PubMed ID: 36841928
[TBL] [Abstract][Full Text] [Related]
10. The association between human leukocyte antigen eplet mismatches, de novo donor-specific antibodies, and the risk of acute rejection in pediatric kidney transplant recipients.
Sharma A; Taverniti A; Graf N; Teixeira-Pinto A; Lewis JR; Lim WH; Alexander SI; Durkan A; Craig JC; Wong G
Pediatr Nephrol; 2020 Jun; 35(6):1061-1068. PubMed ID: 32065279
[TBL] [Abstract][Full Text] [Related]
11. Class II HLA Eplet Mismatch Is a Risk Factor for De Novo Donor-Specific Antibody Development and Antibody-mediated Rejection in Kidney Transplantation Recipients.
Kishikawa H; Kinoshita T; Hashimoto M; Fukae S; Taniguchi A; Yamanaka K; Nakagawa M; Nishimura K
Transplant Proc; 2018 Oct; 50(8):2388-2391. PubMed ID: 30316363
[TBL] [Abstract][Full Text] [Related]
12. Is the level of HLA eplet mismatch a risk factor for graft loss among kidney transplant recipients who have already formed de novo donor specific antibody?
Wen J; Basu A; Bentall A; Henderson N; Dukek B; Gandhi M; Schinstock C
Hum Immunol; 2021 Apr; 82(4):240-246. PubMed ID: 33618904
[TBL] [Abstract][Full Text] [Related]
13. Human leukocyte antigen eplet mismatching is associated with increased risk of graft loss and rejection after pediatric heart transplant.
Albers EL; Friedland-Little JM; Hong BJ; Kemna MS; Warner P; Law YM
Pediatr Transplant; 2022 Feb; 26(1):e14126. PubMed ID: 34476876
[TBL] [Abstract][Full Text] [Related]
14. Mismatch epitope load predicts de novo-DSA-free survival in pediatric liver transplantation.
Shin S; Lee M; Dente E; Yazigi N; Khan KM; Kaufman SS; Ahn J; Timofeeva OA; Ekong UD
Pediatr Transplant; 2022 Jun; 26(4):e14251. PubMed ID: 35279919
[TBL] [Abstract][Full Text] [Related]
15. HLA-DQ mismatches stimulate de novo donor specific antibodies in heart transplant recipients.
Zhang X; Kransdorf E; Levine R; Patel JK; Kobashigawa JA
Hum Immunol; 2020 Jul; 81(7):330-336. PubMed ID: 32307126
[TBL] [Abstract][Full Text] [Related]
16. Comparison of human leukocyte antigen immunologic risk stratification methods in lung transplantation.
Hiho SJ; Levvey BJ; Diviney MB; Snell GI; Sullivan LC; Westall GP
Am J Transplant; 2024 May; 24(5):827-838. PubMed ID: 37981213
[TBL] [Abstract][Full Text] [Related]
17. HLA B eplet mismatches in the context of delayed graft function and low tacrolimus trough levels are risk factors influencing the generation of de novo donor-specific antibodies and acute rejection in the early stage after kidney transplantation.
Gao S; Gong H; Li M; Lan P; Zhang M; Kuang P; Zhang Y; Hu X; Ding C; Li Y; Ding X; Xue W; Zheng J
Transpl Immunol; 2023 Dec; 81():101955. PubMed ID: 37931666
[TBL] [Abstract][Full Text] [Related]
18. Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes.
Wiebe C; Pochinco D; Blydt-Hansen TD; Ho J; Birk PE; Karpinski M; Goldberg A; Storsley LJ; Gibson IW; Rush DN; Nickerson PW
Am J Transplant; 2013 Dec; 13(12):3114-22. PubMed ID: 24164958
[TBL] [Abstract][Full Text] [Related]
19. The Accuracy of Sequence-Specific Oligonucleotide and Real-Time Polymerase Chain Reaction HLA Typing in Determining the Presence of Pre-Transplant Donor-Specific Anti-HLA Antibodies and Total Eplet Mismatches for Deceased Donor Kidney Transplantation.
Larkins NG; D'Orsogna L; Taverniti A; Sharma A; Chakera A; Chan D; Krishnan A; Wong G; Lim WH
Front Immunol; 2022; 13():844438. PubMed ID: 35799779
[TBL] [Abstract][Full Text] [Related]
20. Analysis of T and B Cell Epitopes to Predict the Risk of
Sakamoto S; Iwasaki K; Tomosugi T; Niemann M; Spierings E; Miwa Y; Horimi K; Takeda A; Goto N; Narumi S; Watarai Y; Kobayashi T
Front Immunol; 2020; 11():2000. PubMed ID: 32973806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
